Is Abbott trying to buy its way back into the drug biz?

Abbott Laboratories ($ABT) has largely focused on medical devices and diagnostics since spinning its innovative drugs business off into AbbVie ($ABBV), but Reuters reports the company is bidding on Brazilian drugmaker Aché Laboratorios Farmaceuticos, which could be worth up to $5 billion. Abbott joins Pfizer ($PFE) and Novartis ($NVS) in the running to acquire the privately held company, Reuters' sources say, but the deal could stall if one of the controlling families declines to sell its stake. Report | More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.